These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 34656876)

  • 1. Safety and efficacy of aviandr in patients with generalized anxiety disorder: A multicenter, randomized, double-blind, placebo-controlled, dose-finding, pilot study.
    Ivashchenko AA; Morozova MA; Vostokova NV; Beniashvily AG; Bukhanovskaya OA; Burminskiy DS; Egorova AN; Gluskina LY; Gorchakov DS; Karapetian RN; Kasimova LN; Kravchenko DV; Lepilkina TA; Merkulova EA; Mitkin OD; Penchul NA; Potanin SS; Rupchev GE; Ivachtchenko AV
    J Psychiatr Res; 2021 Nov; 143():436-444. PubMed ID: 34656876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended Release Guanfacine in Pediatric Anxiety Disorders: A Pilot, Randomized, Placebo-Controlled Trial.
    Strawn JR; Compton SN; Robertson B; Albano AM; Hamdani M; Rynn MA
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):29-37. PubMed ID: 28165762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial.
    Gundugurti PR; Banda N; Yadlapalli SSR; Narala A; Thatikonda R; Kocherlakota C; Kothapalli KS
    Asian J Psychiatr; 2024 Jul; 97():104073. PubMed ID: 38797087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of 'antianxiety granule' for anxiety disorder: a multicentre, randomized, double-blind, placebo-controlled, parallel-group trial.
    Sha Z; Hou Y; Xue C; Li O; Li Z; Wang H; Zhang W; Xu J
    Trials; 2020 Jan; 21(1):107. PubMed ID: 31973702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of cranial electrotherapy stimulation as an add-on therapy on late-life generalized anxiety disorder: An open-label study.
    Chu CS; Chang CH; Pan CC; Chiang YC; Kuo HY; Hsu TW; Chen SL; Chen CS
    J Formos Med Assoc; 2024 Jul; 123(7):781-787. PubMed ID: 38485555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcranial Photobiomodulation with Near-Infrared Light for Generalized Anxiety Disorder: A Pilot Study.
    Maiello M; Losiewicz OM; Bui E; Spera V; Hamblin MR; Marques L; Cassano P
    Photobiomodul Photomed Laser Surg; 2019 Oct; 37(10):644-650. PubMed ID: 31647775
    [No Abstract]   [Full Text] [Related]  

  • 7. A standardized Ashwagandha root extract alleviates stress, anxiety, and improves quality of life in healthy adults by modulating stress hormones: Results from a randomized, double-blind, placebo-controlled study.
    Majeed M; Nagabhushanam K; Mundkur L
    Medicine (Baltimore); 2023 Oct; 102(41):e35521. PubMed ID: 37832082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disability and health-related quality of life in outpatients with generalised anxiety disorder treated in psychiatric clinics: is there still room for improvement?
    Bobes J; Caballero L; Vilardaga I; Rejas J
    Ann Gen Psychiatry; 2011 Mar; 10(1):7. PubMed ID: 21401940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amelioration of Anxiety Associated with Opioid Withdrawal by Activation of Spinal Mechanoreceptors Via Novel Heterodyned Whole Body Vibration.
    Sant DW; Nelson CA; Petrie J; Blotter JD; Feland JB; Adams D; Burrows M; Yorgason JT; Schilaty ND; Manwaring KH; Bills KB; Steffensen SC
    J Psychiatry Cogn Behav; 2024; 8(1):. PubMed ID: 38798753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corrigendum to "Clinical efficacy of Shugan granule in the treatment of mixed anxiety-depressive disorder: A multicenter, randomized, double-blind, placebo-controlled trial" [J. Ethnopharmacol. 290 (2022) 115032].
    Li Y; Li L; Guo R; Yu H; Wang X; Wang B; Wang Q; Li Z; Zhao H; Temu Q; Chen X; Zhang Y; An J; Cai X; Li A; Qi L; Shang J; He H; Yang D; Lin J; Zhang Y; Zou T
    J Ethnopharmacol; 2024 Jan; 319(Pt 1):117370. PubMed ID: 37923593
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy.
    Kim R; Kwon M; An M; Kim ST; Smith SA; Loembé AB; Mortimer PGS; Armenia J; Lukashchuk N; Shah N; Dean E; Park WY; Lee J
    Ann Oncol; 2022 Feb; 33(2):193-203. PubMed ID: 34710570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial.
    Kehoe PG; Turner N; Howden B; Jarutyte L; Clegg SL; Malone IB; Barnes J; Nielsen C; Sudre CH; Wilson A; Thai NJ; Blair PS; Coulthard E; Lane JA; Passmore P; Taylor J; Mutsaerts HJ; Thomas DL; Fox NC; Wilkinson I; Ben-Shlomo Y;
    Lancet Neurol; 2021 Nov; 20(11):895-906. PubMed ID: 34687634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study.
    Ochs-Ross R; Wajs E; Daly EJ; Zhang Y; Lane R; Lim P; Drevets WC; Steffens DC; Sanacora G; Jamieson C; Hough D; Manji H; Singh JB
    Am J Geriatr Psychiatry; 2022 May; 30(5):541-556. PubMed ID: 34750057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study.
    Aussedat G; Maucort-Boulch D; Rey P; Safar V; Karlin L; Elsensohn MH; Bachy E; Lebras L; Favier B; Vantard N; Ghergus D; Golfier C; Sesques P; Lazareth A; Lequeu H; Ferrant E; Salles G; Nicolas-Virelizier E; Ghesquieres H
    Leuk Lymphoma; 2022 Mar; 63(3):599-607. PubMed ID: 34720034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study.
    Wang P; Li Y; Lv D; Yang L; Ding L; Zhou J; Hong W; Chen Y; Zhang D; He S; Zhou J; Wang K
    Signal Transduct Target Ther; 2021 Nov; 6(1):374. PubMed ID: 34719670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load.
    Dougan M; Azizad M; Mocherla B; Gottlieb RL; Chen P; Hebert C; Perry R; Boscia J; Heller B; Morris J; Crystal C; Igbinadolor A; Huhn G; Cardona J; Shawa I; Kumar P; Blomkalns A; Adams AC; Van Naarden J; Custer KL; Knorr J; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Sabo J; Patel DR; Dabora MC; Williams M; Klekotka P; Shen L; Skovronsky DM; Nirula A
    Clin Infect Dis; 2022 Aug; 75(1):e440-e449. PubMed ID: 34718468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia.
    Zeidner JF; Lin TL; Vigil CE; Fine G; Yair Levy M; Nazha A; Esteve J; Lee DJ; Yee K; Dalovisio A; Wang ES; Bergua Burgues JM; Schriber J; Litzow MR; Frankfurt O; Castillo TBD; Bhatt VR; Bhatnagar B; Mehta P; Dillon R; Vicente MV; Anthony S; Bearss D; Montesinos P; Douglas Smith B
    Blood Cancer J; 2021 Oct; 11(10):175. PubMed ID: 34718324
    [No Abstract]   [Full Text] [Related]  

  • 18. Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis.
    Song Y; Gao Q; Zhang H; Fan L; Zhou J; Zou D; Li W; Yang H; Liu T; Wang Q; Lv F; Guo H; Zhao X; Wang D; Zhang P; Wang Y; Wang L; Liu T; Zhang Y; Shen Z; Huang J; Zhu J
    Clin Cancer Res; 2022 Mar; 28(6):1147-1156. PubMed ID: 34716199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas.
    Meric-Bernstam F; Sweis RF; Hodi FS; Messersmith WA; Andtbacka RHI; Ingham M; Lewis N; Chen X; Pelletier M; Chen X; Wu J; McWhirter SM; Müller T; Nair N; Luke JJ
    Clin Cancer Res; 2022 Feb; 28(4):677-688. PubMed ID: 34716197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
    Tap WD; Singh AS; Anthony SP; Sterba M; Zhang C; Healey JH; Chmielowski B; Cohn AL; Shapiro GI; Keedy VL; Wainberg ZA; Puzanov I; Cote GM; Wagner AJ; Braiteh F; Sherman E; Hsu HH; Peterfy C; Gelhorn HL; Ye X; Severson P; West BL; Lin PS; Tong-Starksen S
    Clin Cancer Res; 2022 Jan; 28(2):298-307. PubMed ID: 34716196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.